Home Newsfeeds Needham Maintains Buy on CoStar Gr, Raises Price Target to $95

Needham Maintains Buy on CoStar Gr, Raises Price Target to $95

Needham analyst Mayank Tandon maintains CoStar Gr (NASDAQ:CSGP) with a Buy and raises the price target from $80 to $95.

byBenzinga Newsdesk

October 26, 2022

1 minute read

Needham analyst Mayank Tandon maintains CoStar Gr (NASDAQ:CSGP) with a Buy and raises the price target from $80 to $95.

SVB Leerink Upgrades Agios Pharmaceuticals to Outperform, Maintains $33 Price Target

By Benzinga Newsdesk

July 27, 7:07 AM

SVB Leerink analyst Andrew Berens upgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Market Perform to Outperform and maintains $33 price target.

AGIO

Analyst Ratings

8 Analysts Have This to Say About Omega Healthcare Invts

By Benzinga Insights

November 27, 12:00 PM

Over the past 3 months, 8 analysts have published their opinion on Omega Healthcare Invts (NYSE:OHI) stock. These…

OHI

Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?

By Vandana Singh

November 6, 11:27 AM

Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients

CLDX

DocuSign Q1 Earnings: Revenue Beat, EPS Beat, $1B Buyback Increase And More

By Adam Eckert

June 6, 4:28 PM

DocuSign's first-quarter revenue increased 7% year-over-year to $709.6 million, beating the consensus estimate of $707.133 million, according to Benzinga Pro.

DOCU

Needham Maintains Buy on CoStar Gr, Raises Price Target to $95

Related Posts

SVB Leerink Upgrades Agios Pharmaceuticals to Outperform, Maintains $33 Price Target

8 Analysts Have This to Say About Omega Healthcare Invts

Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?

DocuSign Q1 Earnings: Revenue Beat, EPS Beat, $1B Buyback Increase And More